Cited by 261Liver physiology and pathologyDrug Transport and Resistance MechanismsNuclear Receptors and Signaling

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Nuclear Receptors in Liver Disease Δ

Open access

Wagner, Martin, Zollner, Gernot, Trauner, Michael·2011·Hepatology

Open this paper in CoChat — free account Open PDF

Abstract

Nuclear receptors are ligand-activated transcriptional regulators of several key aspects of hepatic physiology and pathophysiology. As such, nuclear receptors control a large variety of metabolic processes including hepatic lipid metabolism, drug disposition, bile acid homeostasis, as well as liver regeneration, inflammation, fibrosis, cell differentiation, and tumor formation. Derangements of nuclear receptor regulation and genetic variants may contribute to the pathogenesis and progression of liver diseases. This places nuclear receptors into the frontline for novel therapeutic approaches for a broad range of hepatic disorders and diseases including cholestatic and fatty liver disease, drug hepatotoxicity, viral hepatitis, liver fibrosis, and cancer. (Hepatology 2011;.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/hep.24148

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,165
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,285
Nuclear Receptor Coregulators and Human Disease
Lonard, D. M., Lanz, R. B., & O’Malley, B. W. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0012 · Cited by 318
Nuclear receptors: Decoding metabolic disease
Sonoda, J., Pei, L., & Evans, R. M. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.11.016 · Cited by 313
Nuclear receptor regulation of hepatic function
Karpen, S. J. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00129-0 · Cited by 173
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases
Arrese, M., & Karpen, S. J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.2 · Cited by 54

Flagged first, then by citations

Show all 7 references

Sorted by citations

Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
Halilbasic, E., Claudel, T., & Trauner, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.002 · Cited by 415
Self-citation
Free radical biology for medicine: learning from nonalcoholic fatty liver disease
Serviddio, G., Bellanti, F., & Vendemiale, G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.174 · Cited by 272
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 275
Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism
Pathak, P., Liu, H., Boehme, S., Xie, C., Krausz, K. W., Gonzalez, F. J., & Chiang, J. Y. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784322 · Cited by 265
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules
Copple, B. L., & Li, T. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.007 · Cited by 238
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Alcoholic liver disease: Pathogenesis, management, and novel targets for therapy
Orman, E. S., Òdena, G., & Bataller, R. A. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12030 · Cited by 233
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Trauner, M., Fuchs, C. D., Halilbasic, E., & Paumgartner, G. (2017) · Hepatology · doi:10.1002/hep.28991 · Cited by 227
Self-citation
The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
Cai, J., Zhang, X., & Li, H. (2019) · Hepatology · doi:10.1002/hep.30506 · Cited by 207
Crosstalk between Oxidative Stress and Inflammatory Liver Injury in the Pathogenesis of Alcoholic Liver Disease
Yang, Y. M., Cho, Y. E., & Hwang, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020774 · Cited by 207
Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis
Baghdasaryan, A., Fuchs, C. D., Österreicher, C. H., Lemberger, U. J., Halilbasic, E., Påhlman, I., Graffner, H., Krones, E., Fickert, P., Wahlström, A., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.024 · Cited by 187
Self-citation
The solute carrier family 10 (SLC10): Beyond bile acid transport
da Silva, T. C., Polli, J. E., & Swaan, P. W. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.004 · Cited by 195
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
Schwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.005 · Cited by 178
Self-citation
Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6
Tao, R., Xiong, X., DePinho, R. A., Deng, C., & Dong, X. C. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m039339 · Cited by 183
Nuclear receptors in bile acid metabolism
Li, T., & Chiang, J. Y. L. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.740048 · Cited by 176
Predicting Hepatotoxicity Using ToxCastin VitroBioactivity and Chemical Structure
Liu, J., Mansouri, K., Judson, R., Martin, M. T., Hong, H., Chen, M., Xu, X., Thomas, R. S., & Shah, I. (2015) · Chemical Research in Toxicology · doi:10.1021/tx500501h · Cited by 166
Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism
Oehler, N., Volz, T., Bhadra, O. D., Kah, J., Allweiss, L., Giersch, K., Bierwolf, J., Riecken, K., Pollok, J. M., Lohse, A. W., et al. (2014) · Hepatology · doi:10.1002/hep.27159 · Cited by 162
Relationship of Non-alcoholic Fatty Liver Disease With Cholecystectomy in the US Population
Ruhl, C. E., & Everhart, J. E. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.70 · Cited by 149
RORα controls hepatic lipid homeostasis via negative regulation of PPARγ transcriptional network
Kim, K., Boo, K.-J., Yu, Y. S., Oh, S. K., Kim, H.-K., Jeon, Y., Bhin, J., Hwang, D., Kim, K. I., Lee, J.-S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00215-1 · Cited by 154
Chronic perfluorooctane sulfonate (PFOS) exposure induces hepatic steatosis in zebrafish
Cheng, J., Lv, S., Nie, S., Liu, J., Tong, S., Kang, N., Xiao, Y., Dong, Q., Huang, C., & Yang, D. (2016) · Aquatic Toxicology · doi:10.1016/j.aquatox.2016.04.013 · Cited by 148
Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M., & Hashimoto, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.041 · Cited by 143
Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities
Idalsoaga, F., Kulkarni, A. V., Mousa, O. Y., Arrese, M., & Arab, J. P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00448 · Cited by 136
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis
Bellanti, F., Villani, R., Facciorusso, A., Vendemiale, G., & Serviddio, G. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.023 · Cited by 136
Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors
Cassol, E., Misra, V., Holman, A. G., Kamat, A., Morgello, S., & Gabuzda, D. H. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-203 · Cited by 128
Ethanol and liver: Recent insights into the mechanisms of ethanol-induced fatty liver
Liu, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14672 · Cited by 125
miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
Rodrigues, P. M., Afonso, M. B., Simão, A. L., Carvalho, C. C., Trindade, A., Duarte, A., Borralho, P. M., Machado, M. V., Cortez‐Pinto, H., Rodrigues, C. M., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.172 · Cited by 114
Ameliorative effect of naringin in acetaminophen-induced hepatic and renal toxicity in laboratory rats: role of FXR and KIM-1
Adil, M., Kandhare, A. D., Ghosh, P., Venkata, S. K., Raygude, K. S., & Bodhankar, S. L. (2016) · Renal Failure · doi:10.3109/0886022x.2016.1163998 · Cited by 113
Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms
Bitter, A., Rümmele, P., Klein, K., Kandel, B. A., Rieger, J. K., Nussler, A. K., Zanger, U. M., Trauner, M. A., Schwab, M. G., & Burk, O. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1348-x · Cited by 112
Self-citation
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD
Hong, T., Chen, Y., Li, X., & Lü, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6889533 · Cited by 110
Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
Halilbasic, E., Baghdasaryan, A., & Trauner, M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.12.001 · Cited by 100
Self-citation
Curcumin attenuates ethanol‐induced hepatic steatosis through modulating N rf2/ FXR signaling in hepatocytes
Lu, C., Zhang, F., Xu, W., Wu, X., Lian, N., Jin, H., Chen, Q., Chen, L., Shao, J., Wu, L., et al. (2015) · IUBMB Life · doi:10.1002/iub.1409 · Cited by 91
Liver Physiology: Metabolism and Detoxification
Chiang, J. Y. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.04202-7 · Cited by 90
Nuclear receptors as therapeutic targets in liver disease: are we there yet?
Rudraiah, S., Zhang, X., & Wang, L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103209 · Cited by 87
S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor alpha activity in the liver
Kim, K., Pyo, S., & Um, S. H. (2011) · Hepatology · doi:10.1002/hep.25537 · Cited by 86
Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside
Zhang, F., Kong, D., Lu, Y., & Zheng, S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1046-x · Cited by 88
Topics on Drug Metabolism
Paxton, J. W. (2012) · InTech eBooks · doi:10.5772/1180 · Cited by 90
Intrahepatic cholestasis in common chronic liver diseases
Jüngst, C., Berg, T., Cheng, J., Green, R. M., Jia, J., Mason, A. L., & Lammert, F. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12128 · Cited by 82
RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome
Cui, J. Y., & Klaassen, C. D. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.04.010 · Cited by 82
The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease
Aguilar-Olivos, N. E., Carrillo-Córdova, D., Oria‐Hernández, J., Sánchez-Valle, V., Ponciano‐Rodríguez, G., Ramírez-Jaramillo, M., Chablé-Montero, F., Chávez-Tapia, N. C., Uribe, M., & Méndez‐Sánchez, N. (2015) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31170-6 · Cited by 80
Dietary Genistein Alleviates Lipid Metabolism Disorder and Inflammatory Response in Laying Hens With Fatty Liver Syndrome
Lv, Z., Xing, K., Li, G., Liu, D., & Guo, Y. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01493 · Cited by 81
Involvement of SIK3 in Glucose and Lipid Homeostasis in Mice
Uebi, T., Itoh, Y., Hatano, O., Kumagai, A., Sanosaka, M., Sasaki, T., Sasagawa, S., Doi, J., Tatsumi, K., Mitamura, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037803 · Cited by 79
β-Klotho gene variation is associated with liver damage in children with NAFLD
Dongiovanni, P., Crudele, A., Panera, N., Romito, I., Meroni, M., Stefanis, C. D., Palma, A., Comparcola, D., Fracanzani, A. L., Miele, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.011 · Cited by 78
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 85
Protective effects of dioscin against alcohol-induced liver injury
Xu, T., Zheng, L., Xu, L., Yin, L., Qi, Y., Xu, Y., Han, X., & Peng, J. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1148-8 · Cited by 77
Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
Li, G., & Guo, G. L. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.005 · Cited by 77
PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
Colapietro, F., Gershwin, M. E., & Lleò, A. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100188 · Cited by 81
The liver X receptor: A master regulator of the gut–liver axis and a target for non alcoholic fatty liver disease
Ducheix, S., Montagner, A., Théodorou, V., Ferrier, L., & Guillou, H. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.016 · Cited by 79
FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis
Panzitt, K., Jungwirth, E., Krones, E., Lee, J. M., Pollheimer, M. J., Thallinger, G., Kolb-Lenz, D., Xiao, R., Thorell, A., Trauner, M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.014 · Cited by 77
Self-citation
Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population
Kwak, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i20.6287 · Cited by 75
Low‐dose food contaminants trigger sex‐specific, hepatic metabolic changes in the progeny of obese mice
Naville, D., Pinteur, C., Véga, N., Menade, Y., Vigier, M., Bourdais, A. L., Labaronne, E., Debard, C., Luquain‐Costaz, C., Bégeot, M., et al. (2013) · The FASEB Journal · doi:10.1096/fj.13-231670 · Cited by 74
Drug Therapies for Chronic Cholestatic Liver Diseases
Wagner, M., & Fickert, P. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021059 · Cited by 75
Self-citation
5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of Tamoxifen in breast cancer cells
Segala, G., de Médina, P., Iuliano, L., Zerbinati, C., Paillasse, M. R., Noguer, E., Dalenc, F., Payré, B., Jordan, V. C., Record, M., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.031 · Cited by 73
β‐Caryophyllene attenuates palmitate‐induced lipid accumulation through AMPK signaling by activating CB2 receptor in human HepG2 hepatocytes
Kamikubo, R., Kai, K., Tsuji, K., & Akagawa, M. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600197 · Cited by 73
Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease
Ishtiaq, S. M., Rashid, H., Hussain, Z., Arshad, M. I., & Khan, J. A. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09510-2 · Cited by 66
Emerging Roles of SIRT1 in Alcoholic Liver Disease
Ren, R., Wang, Z., Wu, M., & Wang, H. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.49535 · Cited by 67
Distinct Plasma Bile Acid Profiles of Biliary Atresia and Neonatal Hepatitis Syndrome
Zhou, K., Wang, J., Xie, G., Zhou, Y., Yan, W., Pan, W., Che, Y., Zhang, T., Wong, L. L., Kwee, S. A., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00676 · Cited by 66
Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis
Greuter, T., Malhi, H., Gores, G. J., & Shah, V. H. (2017) · JCI Insight · doi:10.1172/jci.insight.95354 · Cited by 67
Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis
Zhang, F., Lu, Y., & Zheng, S. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.11.008 · Cited by 65
Autophagy in liver diseases
Kouroumalis, E., Voumvouraki, A., Augoustaki, A., & Samonakis, D. N. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i1.6 · Cited by 66
Profile of Circulatory Metabolites in an Animal Model of Multiple Sclerosis using Global Metabolomics
Mangalam, A. K. (2013) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000150 · Cited by 65
Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy
Ma, Z., Yu, J. H., Yu, Y., & Liang, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113247 · Cited by 63
Multifaceted Interaction Between Hepatitis B Virus Infection and Lipid Metabolism in Hepatocytes: A Potential Target of Antiviral Therapy for Chronic Hepatitis B
Zhang, J., Ling, N., Yu, L., Peng, M., Hu, P., & Chen, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.636897 · Cited by 59
Pregnane X receptor and drug-induced liver injury
Wang, Y., Chai, S. C., Brewer, C., & Chen, T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.963555 · Cited by 59
Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
Wang, M., Li, L., Xu, Y., Du, J., & Ling, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958428 · Cited by 59
Clinical application of transcriptional activators of bile salt transporters
Baghdasaryan, A., Chiba, P., & Trauner, M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.12.001 · Cited by 57
Self-citation
Role of Transcription Factors in Steatohepatitis and Hypertension after Ethanol: The Epicenter of Metabolism
Ansari, R. A., Husain, K. M., & Rizvi, S. A. A. (2016) · Biomolecules · doi:10.3390/biom6030029 · Cited by 57
Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases
Stanimirov, B., Stankov, K., & Mikov, M. (2015) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60307-6 · Cited by 56
Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study
Chang, Y., Noh, Y.-H., Suh, B.-S., Kim, Y., Sung, E., Jung, H. S., Kim, C., Kwon, M., Yun, K. E., Noh, J., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7110458 · Cited by 55
Med1 Subunit of the Mediator Complex in Nuclear Receptor-Regulated Energy Metabolism, Liver Regeneration, and Hepatocarcinogenesis
Jia, Y., Viswakarma, N., & Reddy, J. K. (2014) · Gene Expression · doi:10.3727/105221614x13919976902219 · Cited by 54
Natural Compounds: A Potential Treatment for Alcoholic Liver Disease?
Yan, J., Nie, Y., Luo, M., Chen, Z., & He, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.694475 · Cited by 54
Recent advances in understanding and managing cholestasis
Wagner, M., & Trauner, M. (2016) · F1000Research · doi:10.12688/f1000research.8012.1 · Cited by 53
Self-citation
Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs)
Okazaki, I., Noro, T., Tsutsui, N., Yamanouchi, E., Kuroda, H., Nakano, M., Yokomori, H., & Inagaki, Y. (2014) · Cancers · doi:10.3390/cancers6031220 · Cited by 55
LXR Agonist Regulates the Carcinogenesis of PCa via the SOCS3 Pathway
Fu, W., Yao, J., Huang, Y. H., Li, Q., Li, W., Chen, Z., He, F., Zhou, Z., & Yan, J. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356662 · Cited by 54
Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models
Vitins, A. P., Kienhuis, A. S., Speksnijder, E. N., Roodbergen, M., Luijten, M., & van der Ven, L. T. M. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1211-0 · Cited by 51
Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?
Kim, M.-S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.8 · Cited by 51
Critical role of RanBP2-mediated SUMOylation of Small Heterodimer Partner in maintaining bile acid homeostasis
Kim, D.-H., Kwon, S., Byun, S., Xiao, Z., Park, S. S., Wu, S.-Y., Chiang, C., KEMPER, B. W., & Kemper, J. K. (2016) · Nature Communications · doi:10.1038/ncomms12179 · Cited by 52
Nuclear Receptors in Nonalcoholic Fatty Liver Disease
López-Velázquez, J. A., Carrillo-Córdova, L. D., Chávez-Tapia, N. C., Uribe, M., & Méndez-Sánchez, N. (2012) · Journal of Lipids · doi:10.1155/2012/139875 · Cited by 48
Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity
Liu, A., Krausz, K. W., Fang, Z., Brocker, C. N., Qu, A., & Gonzalez, F. J. (2014) · Archives of Toxicology · doi:10.1007/s00204-013-1188-0 · Cited by 50
Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms
Guo, C., LaCerte, C., Edwards, J. E., Brouwer, K. R., & Brouwer, K. L. R. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246033 · Cited by 50
PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications
Ishtiaq, S. M., Arshad, M. I., & Khan, J. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108298 · Cited by 48
Identification of Chemerin as a Novel FXR Target Gene Down-Regulated in the Progression of Nonalcoholic Steatohepatitis
Deng, Y., Wang, H., Lu, Y., Liu, S., Zhang, Q., Huang, J. V., Zhu, R., Yang, J., Zhang, R., Zhang, D., et al. (2013) · Endocrinology · doi:10.1210/en.2012-2126 · Cited by 48
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 50
Nuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Self-citation
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
Mohammed, O. S., Attia, H. G., Mohamed, B. M. S. A., Elbaset, M. A., & Fayed, H. M. (2023) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2023.11808 · Cited by 48
The chromatin remodeling protein BRG1 regulates APAP-induced liver injury by modulating CYP3A11 transcription in hepatocyte
Li, N., Kong, M., Zeng, S., Xu, Z., Li, M., Hong, W., Chu, X., Sun, X., Zhu, M., & Xu, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.003 · Cited by 44
Farnesoid X receptor–induced lysine‐specific histone demethylase reduces hepatic bile acid levels and protects the liver against bile acid toxicity
Kim, Y., Fang, S., Byun, S., Seok, S., KEMPER, B. W., & Kemper, J. K. (2014) · Hepatology · doi:10.1002/hep.27677 · Cited by 44
Hepatoprotection of auraptene from peels of citrus fruits against thioacetamide-induced hepatic fibrosis in mice by activating farnesoid X receptor
Gao, X., Wang, C., Ning, C., Liu, K., Wang, X., Liu, Z., Sun, H., Ma, X., Sun, P., & Meng, Q. (2018) · Food & Function · doi:10.1039/c8fo00107c · Cited by 44
Protective Effects of Alisol B 23-Acetate Via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Estrogen-Induced Cholestatic Liver Injury in Mice
Meng, Q., Chen, X., Wang, C., Liu, Q., Sun, H., Sun, P., Huo, X., Liu, Z., Yao, J., & Liu, K. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1727-x · Cited by 44
Identifying causal regulatory SNPs in ChIP-seq enhancers
Huang, D., & Ovcharenko, I. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1318 · Cited by 44
Targeting to the non-genomic activity of retinoic acid receptor-gamma by acacetin in hepatocellular carcinoma
Zeng, W., Zhang, C., Cheng, H., Wu, Y., Liu, J., Chen, Z., Huang, J., Ericksen, R. E., Chen, L., Zhang, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00233-5 · Cited by 42
Nuclear receptors in the cross-talk of drug metabolism and inflammation
Gerbal‐Chaloin, S., Iankova, I., Maurel, P., & Daujat‐Chavanieu, M. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.756011 · Cited by 41
Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis
Glaser, F., John, C., Engel, B., Hoeh, B., Weidemann, S. A., Dieckhoff, J., Stein, S., Becker, N., Casar, C., Schuran, F. A., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.030 · Cited by 41
The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
Rausch, M., Samodelov, S. L., Visentin, M., & Kullak-Ublick, G. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213967 · Cited by 44
Fatty Acids Inhibit LAMP2-Mediated Autophagy Flux via Activating ER Stress Pathway in Alcohol-Related Liver Disease
Guo, W., Zhong, W. H., Hao, L., Dong, H., Sun, X., Yue, R., Li, T., & Zhou, Z. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.002 · Cited by 40
Enhancing growth, liver health, and bile acid metabolism of tilapia (Oreochromis niloticus) through combined cholesterol and bile acid supplementation in plant-based diets
Jiang, J., Lü, X., Dong, L., Tian, J., Zhang, J., Guo, Z., Luo, Y., Cui, Z., Wen, H., & Jiang, M. (2024) · Animal nutrition · doi:10.1016/j.aninu.2024.03.001 · Cited by 39

Authors: Wagner, M., Zollner, G., & Trauner, M.
Affiliations: Baylor College of Medicine (US)
Medical University of Graz (AT)
Medical University of Vienna (AT)
Corresponding author: Trauner, Michael
ORCID: Wagner, Martin
Zollner, Gernot
Trauner, Michael
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-03
Volume: 53
Issue: 3
Pages: 1023-1034
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1002/hep.24148
OpenAlex: W1966064283
Cited by: 260
References: 7
Citations by year: 2026: 3 · 2025: 14 · 2024: 8 · 2023: 4 · 2022: 17 · 2021: 23 · 2020: 12 · 2019: 17 · 2018: 17 · 2017: 21 · 2016: 21 · 2015: 22 · 2014: 24 · 2013: 29 · 2012: 19
FWCI: 16.23
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1645 d)
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
Zenodo (CERN European Organization for Nuclear Research) (submittedVersion)
Funders: Austrian Science Foundation and funding from the European Community's Seventh Framework Programme (P18613-B05, F3008-B05)
FLIP (FP7/2007-2013, HEALTH-F2-2009-241762)
Topics: Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: nuclear receptors, liver disease, hepatic lipid metabolism, bile acid homeostasis, drug disposition, liver regeneration, liver fibrosis, liver inflammation, hepatic steatosis, cholestatic liver disease, drug-induced liver injury, viral hepatitis, liver cancer, transcriptional regulation
MeSH terms: Bile Acids and Salts, Cholestasis, Fatty Liver, Glucose, Hepatitis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Humans, Cholesterol, HDL, Liver, Liver Cirrhosis, Liver Diseases, Liver Regeneration, Transcription, Genetic, Triglycerides, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism, Chemical and Drug Induced Liver Injury, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nuclear Receptors in Liver Disease Δ

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks